Research ArticleCancer
An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma
- Renata Sano1,
- Kateryna Krytska1,
- Colleen E. Larmour1,
- Pichai Raman2,
- Daniel Martinez3,
- Gwenda F. Ligon4,
- Jay S. Lillquist4,
- Ulisse Cucchi5,
- Paolo Orsini5,
- Simona Rizzi5,
- Bruce R. Pawel3,
- Diego Alvarado4 and
- Yael P. Mossé1,6,*
- 1Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA.
- 2Division of Oncology and Center for Biomedical Informatics (CBMi), Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA.
- 3Department of Pathology, Children’s Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
- 4Celldex Therapeutics Inc., New Haven, CT 06511, USA.
- 5Nerviano Medical Sciences S.r.l., Nerviano (MI) 20014, Italy.
- 6Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
- ↵*Corresponding author. Email: mosse{at}chop.edu
See allHide authors and affiliations
Science Translational Medicine 13 Mar 2019:
Vol. 11, Issue 483, eaau9732
DOI: 10.1126/scitranslmed.aau9732
